» Articles » PMID: 35516806

A Multi-Scale Computational Model of Levodopa-Induced Toxicity in Parkinson's Disease

Overview
Journal Front Neurosci
Date 2022 May 6
PMID 35516806
Authors
Affiliations
Soon will be listed here.
Abstract

Parkinson's disease (PD) is caused by the progressive loss of dopaminergic cells in substantia nigra pars compacta (SNc). The root cause of this cell loss in PD is still not decisively elucidated. A recent line of thinking has traced the cause of PD neurodegeneration to metabolic deficiency. Levodopa (L-DOPA), a precursor of dopamine, used as a symptom-relieving treatment for PD, leads to positive and negative outcomes. Several researchers inferred that L-DOPA might be harmful to SNc cells due to oxidative stress. The role of L-DOPA in the course of the PD pathogenesis is still debatable. We hypothesize that energy deficiency can lead to L-DOPA-induced toxicity in two ways: by promoting dopamine-induced oxidative stress and by exacerbating excitotoxicity in SNc. We present a systems-level computational model of SNc-striatum, which will help us understand the mechanism behind neurodegeneration postulated above and provide insights into developing disease-modifying therapeutics. It was observed that SNc terminals are more vulnerable to energy deficiency than SNc somas. During L-DOPA therapy, it was observed that higher L-DOPA dosage results in increased loss of terminals in SNc. It was also observed that co-administration of L-DOPA and glutathione (antioxidant) evades L-DOPA-induced toxicity in SNc neurons. Our proposed model of the SNc-striatum system is the first of its kind, where SNc neurons were modeled at a biophysical level, and striatal neurons were modeled at a spiking level. We show that our proposed model was able to capture L-DOPA-induced toxicity in SNc, caused by energy deficiency.

Citing Articles

Tyrosine Hydroxylase Inhibitors and Dopamine Receptor Agonists Combination Therapy for Parkinson's Disease.

Yi L, Tan E, Zhou Z Int J Mol Sci. 2024; 25(9).

PMID: 38731862 PMC: 11083272. DOI: 10.3390/ijms25094643.


Neuroinflammation following anti-parkinsonian drugs in early Parkinson's disease: a longitudinal PET study.

Terada T, Bunai T, Hashizume T, Matsudaira T, Yokokura M, Takashima H Sci Rep. 2024; 14(1):4708.

PMID: 38409373 PMC: 10897150. DOI: 10.1038/s41598-024-55233-z.


Role of dopamine in the pathophysiology of Parkinson's disease.

Zhou Z, Yi L, Wang D, Lim T, Tan E Transl Neurodegener. 2023; 12(1):44.

PMID: 37718439 PMC: 10506345. DOI: 10.1186/s40035-023-00378-6.


D-DOPA Is a Potent, Orally Bioavailable, Allosteric Inhibitor of Glutamate Carboxypeptidase II.

Gori S, Thomas A, Pal A, Wiseman R, Ferraris D, Gao R Pharmaceutics. 2022; 14(10).

PMID: 36297453 PMC: 9608075. DOI: 10.3390/pharmaceutics14102018.


DOPA Homeostasis by Dopamine: A Control-Theoretic View.

Kleppe R, Waheed Q, Ruoff P Int J Mol Sci. 2021; 22(23).

PMID: 34884667 PMC: 8657751. DOI: 10.3390/ijms222312862.

References
1.
De Vito M, Wagner G . Methamphetamine-induced neuronal damage: a possible role for free radicals. Neuropharmacology. 1989; 28(10):1145-50. DOI: 10.1016/0028-3908(89)90130-5. View

2.
Jankovic J, Aguilar L . Current approaches to the treatment of Parkinson's disease. Neuropsychiatr Dis Treat. 2008; 4(4):743-57. PMC: 2536542. DOI: 10.2147/ndt.s2006. View

3.
Cheng N, Maeda T, Kume T, Kaneko S, Kochiyama H, Akaike A . Differential neurotoxicity induced by L-DOPA and dopamine in cultured striatal neurons. Brain Res. 1996; 743(1-2):278-83. DOI: 10.1016/s0006-8993(96)01056-6. View

4.
Muddapu V, Dharshini S, Chakravarthy V, Gromiha M . Neurodegenerative Diseases - Is Metabolic Deficiency the Root Cause?. Front Neurosci. 2020; 14:213. PMC: 7137637. DOI: 10.3389/fnins.2020.00213. View

5.
Chou T . Derivation and properties of Michaelis-Menten type and Hill type equations for reference ligands. J Theor Biol. 1976; 59(2):253-76. DOI: 10.1016/0022-5193(76)90169-7. View